

C2

--24. A dietary or pharmaceutical product according to claim 1 further comprising vegetable, and/or animal and/or synthetic beta caseins with peptides derived from the hydrolysis of animal, vegetable, and/or synthetic proteins lacking the sequence: Pro-Gly-Pro-Ile-His (SEQ ID NO:1) and Pro-Gly-Pro-Ile-Pro (SEQ ID NO:2) and mixtures thereof.--

--25. A method for preventing insulin-dependent diabetes comprising the administration of a product according to claim 1 to the new born and infants.--

--26. A method for preventing insulin-dependent diabetes comprising the administration of a milk containing recombinant human beta casein to the new born and infants.--

--27. A method according to claim 26 wherein the recombinant human beta casein is obtained by cloning methods, using yeasts, bacteria, fungi or from transgenic animals.--

Kindly cancel claims 1-20.

REMARKS

The Examiner's comments regarding the unity of invention have been noted. The specification has been amended to point out that the present application is a national stage application of a PCT application and no priority documents are required.

Claims 1, 4-8 and 10 were rejected under 35